Background: Cystic fibrosis (CF) is associated with numerous nutritional and health challenges that significantly impact the patient's quality of life and clinical outcomes. Nutritional management plays a vital role in addressing issues such as pancreatic insufficiency, fat malabsorption, vitamin and mineral deficiencies, and complications like CF-related diabetes (CFRD) and liver disease (CFLD). This review provides an overview of the essential nutritional assessment, management strategies, and the role of CFTR modulator therapies in improving the nutritional status and health outcomes in CF patients.
Methods: A comprehensive review of the current literature regarding the nutritional needs, deficiencies, and therapies in CF patients was conducted, including a focus on pancreatic enzyme replacement therapy (PERT), vitamin and mineral supplementation, and the management of bone disease, CFRD, and CFLD. Additionally, the impact of CFTR modulators on nutritional outcomes and related complications was examined.
Results: Nutritional assessment in CF is multifaceted, incorporating clinical, anthropometric, body composition, and biochemical evaluations. Early intervention strategies, including PERT and tailored supplementation, are critical for managing fat-soluble vitamin deficiencies, mineral imbalances, and maintaining adequate body mass. The prevalence of CFRD and CFLD significantly impacts CF management, necessitating regular screening and appropriate treatments. CFTR modulator therapies have led to improvements in lung function and nutritional status, though regular monitoring is essential to prevent complications such as hypervitaminosis, altered lipid metabolism, and insulin sensitivity.
Conclusion: A proactive, individualized approach to nutritional management is essential in CF, emphasizing early intervention, regular screening, and personalized therapy to address the diverse challenges faced by these patients. |
- Wilschanski M, Munck A, Carrion E, Cipolli M, Collins S, Colombo C, et al. ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis. Clinical Nutrition. 2024;43(2):413-45.doi:10.1016/j.clnu.2023.12.017 PMid:38169175
- Kutney KA, Sandouk Z, Desimone M, Moheet A. Obesity in cystic fibrosis. Journal of Clinical & Translational Endocrinology.2021;26:100276.doi:10.1016/j.jcte.2021.100276 PMid:34868883
- Ferreira HdS. Anthropometric assessment of children's nutritional status: a new approach based on an adaptation of Waterlow's classification. BMC pediatrics. 2020;20:1-11. Link
4. Madde A, Okoniewski W, Sanders DB, Ren CL, Weiner DJ, Forno E. Nutritional status and lung function in children with pancreatic-sufficient cystic fibrosis. Journal of Cystic Fibrosis. 2022;21(5):769-76.Link
5. Charatsi A-M, Dusser P, Freund R, Maruani G, Rossin H, Boulier A, et al. Bioelectrical impedance in young patients with cystic fibrosis: Validation of a specific equation and clinical relevance. Journal of Cystic Fibrosis. 2016;15(6):825-33. Link
- McDonald CM. Validation of a nutrition risk screening tool for children and adolescents with cystic fibrosis ages 2-20 years. Journal of pediatric gastroenterology and nutrition. 2008;46(4):438-46. doi:10.1097/MPG.0b013e318156c2db PMid:18367958
- Bailey RL. Overview of dietary assessment methods for measuring intakes of foods, beverages, and dietary supplements in research studies. Current opinion in biotechnology.2021;70:91-6.
doi: 10.1016/j.copbio.2021.02.007 PMid:33714006
- Sankararaman S, Hendrix SJ, Schindler T. Update on the management of vitamins and minerals in cystic fibrosis. Nutrition in Clinical Practice. 2022;37(5):1074-87. doi:10.1002/ncp.10899
PMid:35997322
- Mladěnka P, Macáková K, Kujovská Krčmová L, Javorská L, Mrštná K, Carazo A, et al. Vitamin K-sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity. Nutrition reviews. 2022;80(4):677-98. PMid:34472618 Link
- Brown MB, McCarty NA, Millard-Stafford M. High-sweat Na+ in cystic fibrosis and healthy individuals does not diminish thirst during exercise in the heat. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2011;301(4):R1177-R85.
doi:10.1152/ajpregu.00551.2010 PMid:21813870
- Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. The Journal of pediatrics. 2009;155(6):S73-S93. PMid:19914445 Link
- 1 Somaraju URR, Solis-Moya A. Pancreatic enzyme replacement therapy for people with cystic fibrosis. Cochrane Database of systematic reviews. 2020(8).doi: 10.1002/14651858.CD008227.pub4 PMid:32761612
- 1 Grunert J, Tai A. Crushing pancreatic enzymes with enteral feeds in an extremely premature infant with cystic fibrosis-a novel and effective technique. European Journal of Clinical Nutrition. 2021;75(1):214-7. PMid:32859988 Link
- 14. Stallings VA, Tindall AM, Mascarenhas MR, Maqbool A, Schall JI. Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial. PLoS One. 2020;15(5):e0232685.doi:1371/journal.pone.0232685 PMid:32384122
- 15. FitzSimmons SC, Burkhart GA, Borowitz D, Grand RJ, Hammerstrom T, Durie PR, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. New England Journal of Medicine. 1997;336(18):1283-9.doi:1056/NEJM199705013361803 PMid:9113931
- Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, et al. Guide to bone health and disease in cystic fibrosis. The Journal of Clinical Endocrinology & Metabolism. 2005;90(3):1888-96.doi:10.1210/jc.2004-1629 PMid:15613415
- Haseltine KN, Chukir T, Smith PJ, Jacob JT, Bilezikian JP, Farooki A. Bone mineral density: clinical relevance and quantitative assessment. Journal of Nuclear Medicine. 2021;62(4):446-54.
doi:10.2967/jnumed.120.256180 PMid:33310738
- Putman MS, Anabtawi A, Le T, Tangpricha V, Sermet-Gaudelus I. Cystic fibrosis bone disease treatment: current knowledge and future directions. Journal of Cystic Fibrosis. 2019;18:S56-S65.PMid:31679730 Link
- Pawlaczyk-Kamieńska T, Borysewicz-Lewicka M, Batura-Gabryel H, Cofta S. Oral Care Recommendation for Cystic Fibrosis Patients-Recommendation for Dentists. Journal of Clinical Medicine. 2022;11(10):2756. PMid:35628882 Link
- 2 Pawlaczyk-Kamieńska T, Borysewicz-Lewicka M, Śniatała R, Batura-Gabryel H, Cofta S. Dental and periodontal manifestations in patients with cystic fibrosis-A systematic review. Journal of Cystic Fibrosis. 2019;18(6):762-71. PMid:30473190 Link
- Moran A, Pillay K, Becker D, Granados A, Hameed S, Acerini CL. ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis‐related diabetes in children and adolescents. Pediatric diabetes. 2018;19. doi: 10.1111/pedi.12732 PMid:30094886
- Prentice BJ, Jaffe A, Hameed S, Verge CF, Waters S, Widger J. Cystic fibrosis-related diabetes and lung disease: an update. European Respiratory Review. 2021;30(159).
doi:10.1183/16000617.0293-2020 PMid:33597125
- Ode KL, Ballman M, Battezzati A, Brennan A, Chan CL, Hameed S, et al. ISPAD Clinical Practice Consensus Guidelines 2022: management of cystic fibrosis‐related diabetes in children and adolescents. Pediatric diabetes. 2022;23(8):1212. doi:10.1111/pedi.13453 PMid:36537525
- Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World Journal of Hepatology. 2021;13(11):1727. PMid:34904041 Link
- Mailhot G, Denis MH, Beauchamp‐Parent C, Jomphe V. Nutritional management of people living with cystic fibrosis throughout life and disease continuum: changing times, new challenges. Journal of Human Nutrition and Dietetics. 2023;36(5):1675-91. doi:10.1111/jhn.13214 PMid:37515397
- Staufer K. Current treatment options for cystic fibrosis-related liver disease. International journal of molecular sciences. 2020;21(22):8586. doi:10.3390/ijms21228586 PMid:33202578
- Bacalhau M, Camargo M, Magalhães-Ghiotto GA, Drumond S, Castelletti CHM, Lopes-Pacheco M. Elexacaftor-Tezacaftor-Ivacaftor: a life-changing triple combination of CFTR modulator drugs for cystic fibrosis. Pharmaceuticals. 2023;16(3):410. PMid:36986509 Link
- Caley L, Jarosz-Griffiths H, Smith L, Gale L, Barrett J, Kinsey L, et al. Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis. Journal of Cystic Fibrosis. 2023;22(6):1002-9. PMid:37422432 Link
- Fabricius D, Knieling T, Zurmuehl N, Makedon L, Freihorst J, Schmidt H, et al. Changes in vitamins and trace elements after initiation of highly effective CFTR modulator therapy in children and adults with cystic fibrosis-a real-life insight. Molecular and Cellular Pediatrics. 2024;11(1):4.
PMid:38717689 Link
- Gaines H, Jones KR, Lim J, Medhi NF, Chen S, Scofield RH. Effect of CFTR modulator therapy on cystic fibrosis-related diabetes. Journal of Diabetes and its Complications. 2021;35(6):107845.
doi: 10.1016/j.jdiacomp.2020.107845 PMid:33558149
- Talamo Guevara M, McColley SA. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. Expert opinion on drug safety. 2017;16(11):1305-11.
doi: 10.1080/14740338.2017.1372419 PMid:28846049
- Petersen MC, Begnel L, Wallendorf M, Litvin M. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. Journal of Cystic Fibrosis. 2022;21(2):265-71. PMid:34862121 Link
|
